• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Why Weakness in Sarepta Therapeutics Is Likely to Continue

The trading days between the gaps look like an island surrounded by water.
By BRUCE KAMICH
Mar 17, 2023 | 01:20 PM EDT
Stocks quotes in this article: SRPT

Sarepta Therapeutics (SRPT) opened sharply lower Friday on the heels of a FDA advisory meeting for its muscular dystrophy treatment. Let's check the charts and indicators for clues. 

In the daily bar chart of SRPT, below, I can see that share prices gapped higher in early March and then chopped sideways until Friday morning. With the shares gaping lower Friday the March price action looks like an island top reversal pattern. An island top reversal pattern consists of a rising stock that gaps higher on bullish news. The stock stays higher for several days and then the stock gaps lower on disappointing news.

The trading days between the gaps look like an island surrounded by water -- use your imagination. SRPT also gapped below the 50-day moving average line. The rising 200-day moving average line interests below the market in the $110 area.

Trading volume has been very heavy. The daily On-Balance-Line (OBV) line shows weakness from early March. The Moving Average Convergence Divergence (MACD) oscillator has crossed to the downside for a take profit sell signal. 

 
 
 
In the weekly Japanese candlestick chart of SRPT, below, I see a vulnerable-looking picture. Prices are making a top reversal pattern. Top reversals can start a downtrend or they can start a sideways move.
 
The trading volume shows a sharp rise in recent weeks and that can mean that new longs have come in at relatively high price levels. A small price dip can put these late buyers at a loss. The weekly OBV line shows strength from June but could now be reversing. The MACD oscillator recently turned to the upside but that signal could be quickly reversed. 
 
 
 
In this daily Point and Figure chart of SRPT, below, I can see the recent reversal without the price gaps. Here the software projects the $85 area as a price target. 
 
 
In this weekly Point and Figure chart of SRPT, below, I can see an upside price target in the $243 area but a trade at $115.37 should weaken the picture. 
 
 
 
Bottom-line strategy: Island reversal patterns are not rare but I always find them interesting -- first you are bullish with a gap to the upside and then you turn bearish with a gap to the downside. SRPT is likely to see further price weakness in the weeks ahead.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of theStreet are prohibited from trading individual securities.

TAGS: Investing | Technical Analysis | Healthcare | Pharmaceuticals | Drug Approvals

More from Healthcare

Boston Scientific's Wicked Rally Can Take the Stock 20% Higher

Bruce Kamich
Mar 21, 2023 2:59 PM EDT

BSX has rallied the past nine months.

When Will AbbVie's Long-Term Trend Reassert Itself?

Bruce Kamich
Mar 17, 2023 9:28 AM EDT

Let's drill down on the charts.

3 High Dividend Healthcare Stocks for Passive Income

Bob Ciura
Mar 11, 2023 7:15 AM EST

These recession-resilient names offer above-average dividend yields and decent growth prospects.

Here's How Innovation Can Drive Apple Higher

Ed Ponsi
Mar 7, 2023 10:30 AM EST

The tech giant's stock won a buy rating from Goldman Sachs, and its work on a medical innovation could be a game-changer.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login